Liquidia (LQDA) presents new YUTREPIA data at the US Pulmonary Hypertension Association (PHA)s International Annual conference in Dallas, June 11-14, 2026

Earlier this month, Liquidia Corporation presented four posters at the US Pulmonary Hypertension Association (PHA)’s International Conference in Dallas, sharing 24‑week ASCENT study data and broader insights on YUTREPIA (treprostinil) inhalation powder in pulmonary hypertension. Beyond clinical outcomes, the company highlighted patient‑reported cough data, the mental health strain on caregivers and the evolving role of […]

Liquidia (LQDA) presents new YUTREPIA data at the US Pulmonary Hypertension Association (PHA)s International Annual conference in Dallas, June 11-14, 2026 Read Post »

World Pulmonary Hypertension Symposium: Barcelona, June 29-30/July 1, 2024

The World Pulmonary Hypertension Symposia (WSPH) series, started in Geneva in 1973, have been held every 5 years since the Evian edition in 1998: Venice 2003, Dana Point 2008, Nice 2013, Nice 2018. The WSPH have become a traditional appointment among the most authoritative pulmonary hypertension scholars worldwide. They have marked the progresses in pulmonary

World Pulmonary Hypertension Symposium: Barcelona, June 29-30/July 1, 2024 Read Post »

TRANSLATE »
Scroll to Top